These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 33917020)

  • 41. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
    Wittayanukorn S; Qian J; Johnson BS; Hansen RA
    J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between venous thromboembolism events and fibrates: A comparative study.
    Dolladille C; Humbert X; Faucon M; Tournilhac C; Sassier M; Fedrizzi S; Milliez P; Lelong-Boulouard V; Coquerel A; Puddu PE; Parienti JJ; Alexandre J
    Therapie; 2019 Jun; 74(3):421-430. PubMed ID: 30482666
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis.
    Dolladille C; Font J; Bejan-Angoulvant T; Zaman K; Sassier M; Ezine E; Stefan A; Plane AF; Legallois D; Milliez P; Parienti JJ; Alexandre J
    Arch Cardiovasc Dis; 2020; 113(6-7):420-432. PubMed ID: 32418884
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database.
    Meng L; Yang B; Qiu F; Jia Y; Sun S; Yang J; Huang J
    Front Med (Lausanne); 2021; 8():594043. PubMed ID: 33598469
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS.
    Fujimoto M; Hosomi K; Takada M
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):259-66. PubMed ID: 24472404
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems.
    Raschi E; Poluzzi E; Salvo F; Pariente A; De Ponti F; Marchesini G; Moretti U
    Nutr Metab Cardiovasc Dis; 2018 Jun; 28(6):533-542. PubMed ID: 29625780
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
    Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
    Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS).
    Perlman A; Wanounou M; Goldstein R; Choshen Cohen L; Singer DE; Muszkat M
    CNS Drugs; 2019 Dec; 33(12):1223-1228. PubMed ID: 31686406
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
    O'Connell KA; Wood JJ; Wise RP; Lozier JN; Braun MM
    JAMA; 2006 Jan; 295(3):293-8. PubMed ID: 16418464
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system.
    Antonazzo IC; Poluzzi E; Forcesi E; Salvo F; Pariente A; Marchesini G; De Ponti F; Raschi E
    Acta Diabetol; 2020 Jan; 57(1):71-80. PubMed ID: 31203438
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events.
    Rahman MM; Scalese MJ; Hansen RA
    Ann Pharmacother; 2017 Jul; 51(7):563-569. PubMed ID: 28166651
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer.
    Thill M; Schmidt M
    Ther Adv Med Oncol; 2018; 10():1758835918793326. PubMed ID: 30202447
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS).
    Cirmi S; El Abd A; Letinier L; Navarra M; Salvo F
    Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32235443
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.
    Pariente A; Gregoire F; Fourrier-Reglat A; Haramburu F; Moore N
    Drug Saf; 2007; 30(10):891-8. PubMed ID: 17867726
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
    Scott IC; Hider SL; Scott DL
    Drug Saf; 2018 Jul; 41(7):645-653. PubMed ID: 29500799
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
    Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
    Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
    Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
    Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thromboembolism as the adverse event of combined oral contraceptives in Japan.
    Sugiura K; Kobayashi T; Ojima T
    Thromb Res; 2015 Dec; 136(6):1110-5. PubMed ID: 26475406
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database.
    Suzuki Y; Suzuki H; Umetsu R; Uranishi H; Abe J; Nishibata Y; Sekiya Y; Miyamura N; Hara H; Tsuchiya T; Kinosada Y; Nakamura M
    Biol Pharm Bull; 2015; 38(5):680-6. PubMed ID: 25947914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.